Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Type I keratoprosthesis for visual rehabilitation of patients with xeroderma pigmentosum

View through CrossRef
A 6-year-old girl, a case of xeroderma pigmentosum (XP), presented with a visual acuity (VA) of 20/20 and 20/400 in the right and left eye, respectively. For a diagnosis of vascularised corneal scar, penetrating keratoplasty was performed in the left eye twice and ultimately graft failed following multiple episodes of rejection. Type I keratoprosthesis was performed in the left eye. She continues to maintain VA of 20/40 in the left eye for more than a year. Similarly, a 24-year-old man, a case of XP, presented with VA of finger counting at 1 metre in both eyes. Ocular examination showed bilateral vascularised corneal scar and conjunctivalisation. Type I keratoprosthesis was performed as primary procedure in the left eye. He maintains a VA of 20/30 for more than a year. Type I keratoprosthesis could be a primary procedure for visual rehabilitation in patients with XP with severe ocular surface disease.
Title: Type I keratoprosthesis for visual rehabilitation of patients with xeroderma pigmentosum
Description:
A 6-year-old girl, a case of xeroderma pigmentosum (XP), presented with a visual acuity (VA) of 20/20 and 20/400 in the right and left eye, respectively.
For a diagnosis of vascularised corneal scar, penetrating keratoplasty was performed in the left eye twice and ultimately graft failed following multiple episodes of rejection.
Type I keratoprosthesis was performed in the left eye.
She continues to maintain VA of 20/40 in the left eye for more than a year.
Similarly, a 24-year-old man, a case of XP, presented with VA of finger counting at 1 metre in both eyes.
Ocular examination showed bilateral vascularised corneal scar and conjunctivalisation.
Type I keratoprosthesis was performed as primary procedure in the left eye.
He maintains a VA of 20/30 for more than a year.
Type I keratoprosthesis could be a primary procedure for visual rehabilitation in patients with XP with severe ocular surface disease.

Related Results

A New Model of Temporary Intraoperative Keratoprosthesis
A New Model of Temporary Intraoperative Keratoprosthesis
Relevance. Pen globe injury (OGI) is one of the most severe types of ocular trauma in both peacetime and wartime conditions. Considering the extent of damage to the anterior and po...
Visual Rehabilitation in Patients With Corneal Blindness Using Keratoprosthesis
Visual Rehabilitation in Patients With Corneal Blindness Using Keratoprosthesis
Background and Aims Blindness is one of the major health problems and diseases, such as corneal opacity, cataracts, glaucoma, and age-related macular degeneration due to diabetes a...
Abstract 1787: Prevention of skin cancer in xeroderma pigmentosum: A long-term study of fourteen patients
Abstract 1787: Prevention of skin cancer in xeroderma pigmentosum: A long-term study of fourteen patients
Abstract Xeroderma pigmentosum (XP) is a multigenic, recessively inherited precancerous disorder occurring in approximately 4 per million live births in the United S...
Xeroderma pigmentosum skin: an immune privilege site for tumor development
Xeroderma pigmentosum skin: an immune privilege site for tumor development
A unique feature of the skin immune system is its proximity to cells continuously exposed to sun rays, as it is located in the interface between the body and the environment.In thi...
Xeroderma pigmentosum with bilateral ocular surface squamous neoplasia and review of the literature
Xeroderma pigmentosum with bilateral ocular surface squamous neoplasia and review of the literature
Xeroderma pigmentosum is a rare genetic disorder associated with various ocular malignancies. Here we report a single paediatric case of xeroderma pigmentosum with bilateral ocular...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
PROBLEMATIC ISSUES OF FINANCIAL AND LEGAL SUPPORT FOR INTERNATIONAL AND STATE PROGRAMMES FOR THE REHABILITATION OF VETERANS
PROBLEMATIC ISSUES OF FINANCIAL AND LEGAL SUPPORT FOR INTERNATIONAL AND STATE PROGRAMMES FOR THE REHABILITATION OF VETERANS
This article provides a thorough analysis of the current financial and legal support available for veteran rehabilitation programmes in Ukraine. It highlights the importance of reh...

Back to Top